Management of long COVID has been perplexing with symptoms having functional and possibly inflammatory origins. Colchicine has been studied in long COVID and failed to improve functional capacity, respiratory function, or inflammatory markers.
Dr. John Cush RheumNow
9 months 2 weeks ago
30% of RA pts have non-alcoholic fatty liver disease (NAFLD). In 170 pts on MTX or biologics (TNFi, IL-6i)- NAFLD was found in 36%. MTX & biologics were not linked to NAFLD or fibrosis -- BUT was signif assoc w/ metabolic syndr, BMI, Waist, ALT, and AST (all p < .001) https://t.co/MpkxjHEbxK
Dr. John Cush RheumNow
9 months 2 weeks ago
Bad Actor Cofactor (10.17.2025)
Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more
https://t.co/zDDLwwRSy9 https://t.co/2S8jPOY0Be
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have benefits beyond glycemic control, including cardioprotective and nephroprotective effects, with modest weight loss. Now a recent population study suggests that SGLT-2i may have immunomodulatory effects and the ability to preven autoimmune disease.
Dr. John Cush RheumNow
9 months 2 weeks ago
Telitacicept Effective in Systemic Lupus Erythematosus
The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few https://t.co/lwq8ZUMTQ8
Dr. John Cush RheumNow
9 months 2 weeks ago
SAIL-RA: Finding ILD in Early RA
Cohort study of early rheumatoid arthritis (RA) patients finds that interstitial lung disease (ILD) begins early in the course of RA, with certain factors enhancing this risk.
https://t.co/nI0YuYd3YS https://t.co/YR3Gg1kr59
The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.
Dr. John Cush RheumNow
9 months 2 weeks ago
FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. https://t.co/0eGwGnSDYf https://t.co/Z6w2iP4u3e
Dr. John Cush RheumNow
9 months 2 weeks ago
Retrospective study of 423 seropositiv RA pts (SPRA) finds 21% with baseline ILD; over 10 yrs 31% had ILD. High monocyte counts signif higher in RA-ILD; whereas RF, CCP did not predict. Age & ILD predicted mortality - not monocytes, RF or CCP https://t.co/8H4wqZI3WQ https://t.co/dK9iHwj3cz
Dr. John Cush RheumNow
9 months 2 weeks ago
Interleukin-18 (IL-18) regulates appetite, body weight & glucose homeostasis. IL-18 deficiency may lead to obesity, but chronic IL-18 signalling promotes liver fibrosis. IL-18 is Elevated in obesity and diabetes mellitus https://t.co/Xylvexqvtg https://t.co/sRutSCoLf9
Dr. John Cush RheumNow
9 months 2 weeks ago
Study of biopsy proven lupus nephritis pts (1970-2024) - a total of 324 LN pts followed for median 9.9 yrs -- 30 (9.3%) developed Venous Thromboembolic event (VTE); time from LN to 1st VTE 4.4 yrs. Predictors were SLEDAI-2K score (HR= 1.05) and proteinuria level (HR 1.26)
Dr. John Cush RheumNow
9 months 2 weeks ago
From the plenary to posters, RheumNow is your companion for ACR Convergence 2025. Expect:
• KOL videos
• Clinical trial highlights
• Daily faculty recaps
• Live streaming
#ACR25 #Rheumatology #ClinicalTrials https://t.co/zZAwYINmC2
Dr. John Cush RheumNow
9 months 2 weeks ago
“Never in the field of human conflict was so much owed by so many to so few.” –
Winston Churchill https://t.co/ZAcYBpOmjy
Dr. John Cush RheumNow
9 months 2 weeks ago
Review of IL-1 family cytokines in inflammation and immunity - including, IL-1, IL-18, IL-33, IL-36, IL-37, IL-38, IL-1Ra, etc. Full read -- Good Reference!! https://t.co/m2CwDydnB0 https://t.co/h90bdzv3y7
Dr. John Cush RheumNow
9 months 2 weeks ago
Mediterranean Diet Efficacy in Psoriasis
A small clinical trial found that a 16-week Mediterranean diet reduced psoriasis severity, presumably due to anti-inflammatory benefits of extra virgin olive oil, plant-based foods, and moderate meat consumption, according to a study https://t.co/fiJTx6TEZq
